Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

The binding sites of monoclonal antibodies to the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide.

Lu Z, Rynkiewicz MJ, Yang CY, Madico G, Perkins HM, Wang Q, Costello CE, Zaia J, Seaton BA, Sharon J.

Immunology. 2013 Nov;140(3):374-89. doi: 10.1111/imm.12150.

2.

Protective B-cell epitopes of Francisella tularensis O-polysaccharide in a mouse model of respiratory tularaemia.

Lu Z, Madico G, Roche MI, Wang Q, Hui JH, Perkins HM, Zaia J, Costello CE, Sharon J.

Immunology. 2012 Jul;136(3):352-60. doi: 10.1111/j.1365-2567.2012.03589.x.

3.

Antibodies to both terminal and internal B-cell epitopes of Francisella tularensis O-polysaccharide produced by patients with tularemia.

Lu Z, Perkins HM, Sharon J.

Clin Vaccine Immunol. 2014 Feb;21(2):227-33. doi: 10.1128/CVI.00626-13. Epub 2013 Dec 18.

4.

Functional and structural characterization of Francisella tularensis O-antigen antibodies at the low end of antigen reactivity.

Lu Z, Rynkiewicz MJ, Yang CY, Madico G, Perkins HM, Roche MI, Seaton BA, Sharon J.

Monoclon Antib Immunodiagn Immunother. 2014 Aug;33(4):235-45. doi: 10.1089/mab.2014.0022.

5.

Characterization of monoclonal antibodies to terminal and internal O-antigen epitopes of Francisella tularensis lipopolysaccharide.

Roche MI, Lu Z, Hui JH, Sharon J.

Hybridoma (Larchmt). 2011 Feb;30(1):19-28. doi: 10.1089/hyb.2010.0083.

6.

B-cell epitopes in GroEL of Francisella tularensis.

Lu Z, Rynkiewicz MJ, Madico G, Li S, Yang CY, Perkins HM, Sompuram SR, Kodela V, Liu T, Morris T, Wang D, Roche MI, Seaton BA, Sharon J.

PLoS One. 2014 Jun 26;9(6):e99847. doi: 10.1371/journal.pone.0099847. eCollection 2014.

7.

Structural analysis of a protective epitope of the Francisella tularensis O-polysaccharide.

Rynkiewicz MJ, Lu Z, Hui JH, Sharon J, Seaton BA.

Biochemistry. 2012 Jul 17;51(28):5684-94. Epub 2012 Jul 2.

8.

A typical preparation of Francisella tularensis O-antigen yields a mixture of three types of saccharides.

Wang Q, Shi X, Leymarie N, Madico G, Sharon J, Costello CE, Zaia J.

Biochemistry. 2011 Dec 20;50(50):10941-50. doi: 10.1021/bi201450v. Epub 2011 Nov 28.

9.

Generation and characterization of hybridoma antibodies for immunotherapy of tularemia.

Lu Z, Roche MI, Hui JH, Unal B, Felgner PL, Gulati S, Madico G, Sharon J.

Immunol Lett. 2007 Oct 15;112(2):92-103. Epub 2007 Aug 8.

10.

Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia.

Hickey AJ, Hazlett KR, Kirimanjeswara GS, Metzger DW.

Vaccine. 2011 Sep 16;29(40):6941-7. doi: 10.1016/j.vaccine.2011.07.075. Epub 2011 Jul 29.

11.

Host-adaptation of Francisella tularensis alters the bacterium's surface-carbohydrates to hinder effectors of innate and adaptive immunity.

Zarrella TM, Singh A, Bitsaktsis C, Rahman T, Sahay B, Feustel PJ, Gosselin EJ, Sellati TJ, Hazlett KR.

PLoS One. 2011;6(7):e22335. doi: 10.1371/journal.pone.0022335. Epub 2011 Jul 22.

12.

[Species- and genus-specific antigenic epitopes of Francisella tularensis lipopolysaccharides].

Pavlovich NV, Aronova NV, Onoprienko NN, Sorokin VM, Mazrukho BL.

Mol Gen Mikrobiol Virusol. 2000;(3):7-12. Russian.

PMID:
10975073
13.

[The preventive activity of monoclonal antibodies specific to the lipopolysaccharide of Francisella tularensis].

Khlebnikov VS, Vetchinin SS, Grechko GK, Averina AA, Golovlev IR, Averin SF, Zhemchugov VE, Konovalov SI, Anisimov GA, Afanas'ev SS.

Zh Mikrobiol Epidemiol Immunobiol. 1992;(9-10):67-70. Russian.

PMID:
1481610
14.

Identification, characterization and immunogenicity of an O-antigen capsular polysaccharide of Francisella tularensis.

Apicella MA, Post DM, Fowler AC, Jones BD, Rasmussen JA, Hunt JR, Imagawa S, Choudhury B, Inzana TJ, Maier TM, Frank DW, Zahrt TC, Chaloner K, Jennings MP, McLendon MK, Gibson BW.

PLoS One. 2010 Jul 6;5(7):e11060. doi: 10.1371/journal.pone.0011060.

15.

Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine.

Kim TH, Pinkham JT, Heninger SJ, Chalabaev S, Kasper DL.

J Infect Dis. 2012 Apr 1;205(7):1056-65. doi: 10.1093/infdis/jir620. Epub 2011 Oct 3.

17.

Preparation of monoclonal antibodies for detection and identification of Francisella tularensis.

Hotta A, Uda A, Fujita O, Tanabayashi K, Yamada A.

Clin Vaccine Immunol. 2007 Jan;14(1):81-4. Epub 2006 Nov 22.

18.
19.

Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS.

Li J, Ryder C, Mandal M, Ahmed F, Azadi P, Snyder DS, Pechous RD, Zahrt T, Inzana TJ.

Microbiology. 2007 Sep;153(Pt 9):3141-53.

PMID:
17768257
20.

Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.

Sharon J, Rynkiewicz MJ, Lu Z, Yang CY.

Immunology. 2014 May;142(1):1-23. doi: 10.1111/imm.12213. Review.

Supplemental Content

Support Center